GNRH1 and cancer: Through the subgroup analysis among patients receiving GnRH therapy, interestingly, those younger than 70 years old or at an earlier cancer stage (Stage I/II) were at higher risks of VTEs (adjusted HR: 2.58; 95% CI: 1.21–5.53, p = 0.0147 and adjusted HR: 1.80; CI: 1.05–3.10, p = 0.0332, respectively).